DOCSLIB.ORG

The Art of Eyes 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Art of Eyes 2019 JULY 2019 # 67 Upfront In My View Feature Sitting Down With The outcome-altering FLACS in Can a glaucoma diagnosis Vitreoretinal surgeon, power of anxiety complicated cases do more harm than good? Robert MacLaren 8 12 34 – 41 50 – 51 The Art of Eyes 2019 A selection of beautiful, thought-provoking and inspiring images with one common theme: ophthalmology 14 – 21 www.theophthalmologist.com B:8.875” T:8.3” S:7.8” Enhanced vision within reach. T:10.5” B:11” S:10” A new generation of monofocal IOLs See the Passion • Improved intermediate vision1 in Each Patient. • 20/20 distance vision1* Give them more ING INNOV Enhance your patients’ intermediate vision by AD AT E IO L N | | N H O I using TECNIS Eyhance IOL I G T H C - Q A F U S A I T Reference L I A T S Y L 1. Data on File, Johnson & Johnson Surgical Vision. Inc. Sep 2018. DOF2018CT4015. O A U N T O C I O * Based on a clinical study, N= 134 achieved mean 20/20 monocular pooled distance BCDVA. T P M E E C S X | E For healthcare professionals only. Please read the Directions for Use for Important Safety Information and consult our specialists if you have any questions. TECNIS and TECNIS Eyhance are trademarks of Johnson & Johnson Surgical Vision, Inc. © Johnson & Johnson Surgical Vision, Inc. 2019 | PP2019CT4156 Bring Vision to Life. The Ophthalmologist - EU PP2019CT4156 Ad #: M19JJVS02_01 Bleed: 8.875” x 11” AD: None Headline: Enhanced vision within reach. Trim: 8.3” x 10.5” CW: None Visual: Doctor/patient Live: 7.8” x 10” CD: None Space/Color: CMYK Gutter: None AP: None Publication: Ocular Surgery News PP2019CT4510 PP: Sam Buttrick Project #: PR18477 Document Name: CNY_M19JJVS02_01_01.indd AQR Client: JOHNSON & JOHNSON Document Path: CPNY:ME Production:Johnson_and_Johnson:JJ_Surgical Production:_2019 Magazines: M19JJVS02:CNY_ Studio QA Division: JJV Surgical US M19JJVS02_01_01.indd Product: IOLs US Font Family: Gotham (Medium, Bold, Book; OpenType), Trade Gothic (Bold Condensed No. 20; Type 1) Proofreader Job #: None Ink Name: CMYK Print/Export Time: 6-18-2019 11:42 AM Link Name: CNY_PR18477_Doctor’s_Office_973986222_SWOP_V1.tif (CMYK; 760 ppi; Up to Date; 39.44%), Lines.bmp Art Director CRAFT MagNwp Print Scale: None (Gray; 513 ppi, -514 ppi; Up to Date; 58.38%, -58.38%), Tecnis Eyhance_CMYK.ai (Up to Date; 51.35%), 2017 TECNIS CopyWriter User Name: Ng, Brian (NYC-CWW) Logo Sheet.ai (Up to Date; 30.06%, 28.71%), jnj_Vision_logo_horizontal_cmyk.ai (Up to Date; 57.21%) Proof #: 1 Acct Exec Slug Name: PM: None Release QA InDesign Version: CC 2019 Print Prod B:8.875” T:8.3” S:7.8” Image of the Month Enhanced vision within reach. T:10.5” B:11” S:10” A new generation of monofocal IOLs See the Passion • Improved intermediate vision1 in Each Patient. • 20/20 distance vision1* Give them more ING INNOV Enhance your patients’ intermediate vision by AD AT E IO L N | | N H O I using TECNIS Eyhance IOL I G T H C - Q A F U S A I T Reference L No Magic Bullet I A T S Y L 1. Data on File, Johnson & Johnson Surgical Vision. Inc. Sep 2018. DOF2018CT4015. O A U N T O C I O * Based on a clinical study, N= 134 achieved mean 20/20 monocular pooled distance BCDVA. T P M This month’s image, taken at the slit lamp, shows YAG laser iridotomy with dysphotopsia. E E C S X | E Credit: Julio César Atencio Gutierrez, Ophthalmic Surgeon, Medellin, Colombia For healthcare professionals only. Please read the Directions for Use for Important Safety Information and consult our specialists if you have any questions. TECNIS and TECNIS Eyhance are trademarks of Johnson & Johnson Surgical Vision, Inc. © Johnson & Johnson Surgical Vision, Inc. 2019 | PP2019CT4156 Do you have an image you’d like to see featured in The Ophthalmologist? Contact [email protected] Bring Vision to Life. www.theophthalmologist.com The Ophthalmologist - EU PP2019CT4156 Ad #: M19JJVS02_01 Bleed: 8.875” x 11” AD: None Headline: Enhanced vision within reach. Trim: 8.3” x 10.5” CW: None Visual: Doctor/patient Live: 7.8” x 10” CD: None Space/Color: CMYK Gutter: None AP: None Publication: Ocular Surgery News PP2019CT4510 PP: Sam Buttrick Project #: PR18477 Document Name: CNY_M19JJVS02_01_01.indd AQR Client: JOHNSON & JOHNSON Document Path: CPNY:ME Production:Johnson_and_Johnson:JJ_Surgical Production:_2019 Magazines: M19JJVS02:CNY_ Studio QA Division: JJV Surgical US M19JJVS02_01_01.indd Product: IOLs US Font Family: Gotham (Medium, Bold, Book; OpenType), Trade Gothic (Bold Condensed No. 20; Type 1) Proofreader Job #: None Ink Name: CMYK Print/Export Time: 6-18-2019 11:42 AM Link Name: CNY_PR18477_Doctor’s_Office_973986222_SWOP_V1.tif (CMYK; 760 ppi; Up to Date; 39.44%), Lines.bmp Art Director CRAFT MagNwp Print Scale: None (Gray; 513 ppi, -514 ppi; Up to Date; 58.38%, -58.38%), Tecnis Eyhance_CMYK.ai (Up to Date; 51.35%), 2017 TECNIS CopyWriter User Name: Ng, Brian (NYC-CWW) Logo Sheet.ai (Up to Date; 30.06%, 28.71%), jnj_Vision_logo_horizontal_cmyk.ai (Up to Date; 57.21%) Proof #: 1 Acct Exec Slug Name: PM: None Release QA InDesign Version: CC 2019 Print Prod Contents 50 In My View 12 In Favor of FLACS Boris Malyugin makes the case for lasers, showing the benefits of FLACS in challenging cases 13 Mitigating the MIGS Fear Factor New-generation MIGS devices demonstrate remarkable predictability, argues William Wiley 11 Feature 14 The Art of Eyes 2019 What does a watercolor of 03 Image of the Month Upfront fovea have in common with a photograph taken in rural 08 Sick with Worry Uganda, and a raincloud 07 Editorial doodle? They can all be found in State of the Art(ificial), 09 Bitesize Breakthroughs this year’s edition of our annual by Aleksandra Jones ophthalmic image gallery 10 Shingle White Female 34 Physician, Heal Thyself 11 A Benevolent Action As Raymond Radford claims On The Cover that most patients labeled as JULY 2019 # 67 “glaucoma suspects” carry the Upfront In My View Feature Sitting Down With The outcome-altering FLACS in Can a glaucoma diagnosis Vitreoretinal surgeon, power of anxiety complicated cases do more harm than good? Robert MacLaren 8 12 34 – 41 50 – 51 The captivating image from Carissa burden unnecessarily for many The Art of Eyes 2019 A selection of beautiful, thought-provoking and inspiring images with one common theme: ophthalmology 14 – 21 Hurdstrom uses the human eye to years, five glaucoma specialists represent astronomical objects. respond, discussing unconscious www.theophthalmologist.com bias and surgery risks ISSUE 67 - JULY 2019 Editor - Aleksandra Jones [email protected] Associate Editor - Phoebe Harkin [email protected] Content Director - Rich Whitworth [email protected] Publishing Director - Neil Hanley [email protected] Business Development Executive, America- Ross Terrone [email protected] Associate Publisher- Sam Blacklock [email protected] Business Development Executive- Paul Longley [email protected] Head of Design - Marc Bird [email protected] Designer - Hannah Ennis [email protected] Designer - Charlotte Brittain [email protected] Digital Team Lead - David Roberts [email protected] Digital Producer Web/Email - Peter Bartley [email protected] Digital Producer Web/App - Abygail Bradley [email protected] Audience Insight Manager & Data Protection Officer- Tracey Nicholls [email protected] Traff ic & Audience Database Coordinator - Hayley Atiz [email protected] Project Manager - Webinars - Lindsey Vickers [email protected] Traffic Manager - Jody Fryett [email protected] Traffic Assistant - Dan Marr [email protected] Events Manager - Alice Daniels-Wright [email protected] Event Coordinator - Jessica Lines [email protected] Marketing Manager - Katy Pearson [email protected] Social Media Manager - Joey Relton [email protected] Marketing Executive - Sarah Botha [email protected] Financial Controller - Phil Dale 14 [email protected] Accounts Assistant - Kerri Benson [email protected] Senior Vice President (North America) - Fedra Pavlou [email protected] Chief Executive Officer - Andy Davies [email protected] In Practice Sitting Down With... Chief Operating Officer - Tracey Peers [email protected] 44 Inside Out or Outside In? 50 Robert MacLaren, Change of address/ General enquiries [email protected] Advanced Glaucoma Vitreoretinal Surgeon, Professor Hayley Atiz, The Ophthalmologist, Texere Publishing Limited, Booths Park 1, Chelford Technologies Forum panelists of Ophthalmology, University Road, Knutsford, Cheshire, WA16 8GS, UK www.texerepublishing.com discuss the pros and cons of ab of Oxford, UK +44 (0) 1565 745 200 [email protected] interno and ab externo MIGS Distribution procedures The Ophthalmologist (ISSN 2051-4093), is published monthly by Texere Publishing Limited, Booths Park 1, Chelford Road, Knutsford, Cheshire, WA16 8GS, UK 46 Perspectives: Femtosecond Single copy sales £15 (plus postage, cost available on request [email protected]) Lasers in Cataract Surgery Non-qualified annual subscription cost is £110 plus postage Five cataract experts answer Reprints & Permissions – [email protected] the question: why do some The opinions presented within this publication are those of the authors and do not reflect the opinions of The Ophthalmologist or its publishers, Texere Publishing. ophthalmologists choose to employ Authors are required to disclose any relevant financial arrangements, which are presented at the end of each article, where relevant. FLACS, and some do not? © 2019 Texere Publishing Limited. All rights reserved. Reproduction in whole or in parts is prohibited. www.theophthalmologist.com BIOM® Optic Set – Single-use lenses for BIOM® systems • Ideal for 3D Heads-up surgery Single-use means no scratches or opacities • Maximum precision Superb depth of field even under high magnification • Cost effective No reprocessing costs and reduced O.R.
Load more

Recommended publications
  • Genetic Defects of CHM and Visual Acuity Outcome in 24 Choroideremia
    www.nature.com/scientificreports OPEN Genetic defects of CHM and visual acuity outcome in 24 choroideremia patients from 16 Japanese families Takaaki Hayashi1,2*, Shuhei Kameya3, Kei Mizobuchi2, Daiki Kubota3, Sachiko Kikuchi3, Kazutoshi Yoshitake4, Atsushi Mizota5, Akira Murakami6, Takeshi Iwata4 & Tadashi Nakano2 Choroideremia (CHM) is an incurable progressive chorioretinal dystrophy. Little is known about the natural disease course of visual acuity in the Japanese population. We aimed to investigate the genetic spectrum of the CHM gene and visual acuity outcomes in 24 CHM patients from 16 Japanese families. We measured decimal best-corrected visual acuity (BCVA) at presentation and follow-up, converted to logMAR units for statistical analysis. Sanger and/or whole-exome sequencing were performed to identify pathogenic CHM variants/deletions. The median age at presentation was 37.0 years (range, 5–76 years). The mean follow-up interval was 8.2 years. BCVA of the better-seeing eye at presentation was signifcantly worsened with increasing age (r = 0.515, p < 0.01), with a high rate of BCVA decline in patients > 40 years old. A Kaplan–Meier survival curve suggested that a BCVA of Snellen equivalent 20/40 at follow-up remains until the ffties. Fourteen pathogenic variants, 6 of which were novel [c.49 + 5G > A, c.116 + 5G > A, p.(Gly176Glu, Glu177Ter), p.Tyr531Ter, an exon 2 deletion, and a 5.0-Mb deletion], were identifed in 15 families. No variant was found in one family only. Our BCVA outcome data are useful for predicting visual prognosis and determining the timing of intervention in Japanese patients with CHM variants.
    [Show full text]
  • Robert Maclaren
    INTERVIEW IN CONVERSATION WITH Robert MacLaren, Professor of Ophthalmology, University of Oxford Professor Robert MacLaren gave the Keeler Lecture at the Royal College of Ophthalmologists Annual Meeting in May 2019 on gene therapy for retinitis pigmentosa. We caught up with him afterwards to find out more. people in the developed world, since we now well and we will have treatments available have treatments for diabetic retinopathy. for our patients in the UK, but we’re not quite There is a huge unmet need. We have also got there yet. one gene that has been approved so it is up to us to try and find other genes and get them What do you hope will be made through to clinical trials. possible through gene therapy in the future? There was a lot of media attention The ideal, of course, would be to prevent earlier this year about gene therapy someone from going blind who would trials in age-related macular otherwise loose their sight from a genetic degeneration (AMD). How would disease. Genetic mutations are occurring What are the key messages of your this work? all the time, so when you have a baby, for Keeler Lecture? The concept of gene therapy is to use a virus instance, that child will have 70 mutations Gene therapy is now actually an approved to deliver a gene under the retina to the that are not in the DNA of either the mother treatment, so it is not just about research, retinal epithelium. We’ve demonstrated or the father. Most of them are silent and do but it’s actually something patients can have.
    [Show full text]
  • Programme Book
    SPONSORS AND EXHIBITORS MAIN MAJOR Programme book CIS - INDUSTRY SPONSORED SYMPOSIA OCTOBER 5-8 www.ever.be EVER K SIS - SPECIAL INTEREST SYMPOSIA boo MME A R G 2016 in conjunction ro EUPO EXHIBITORS Science for Sight course with EVER CAMBRIDGE RESEARCH SYSTEMS NICE EVER 2016 P EVER 2016 THANK YOU EVER would like to thank all of its past and present sponsors We would especially like to thank the following companies, many of which are our long-term supporters, for their generous sponsorship in 2016 Thanks to their kind support EVER can continue to encourage research and dissemination of knowledge concerning the eye and vision by means of meetings, publications and exchange of information EVER 2016 - programme book 22 CME XEN_Advertisement_A4 portrait_Ever2016 programme.indd 1 Find alist of countries where XEN is available at the Allergan stand. Adverse events should be reported to your local regulatory authority and Allergan office. XENDate is ofnot preparation:commercially July available 2016 INT/0457/2016a XEN in France. is amedical device class III CE 0086. Please consult your local directions for use. The power of simplicity Rethink glaucoma management glaucoma Rethink 09/08/2016 10:59 HERMES RHODES 1 RHODES 2 RHODES 3 RHODES 4 GALLIENI 1&2 GALLIENI 4 GALLIENI 5 Friday, October 7, 2016 08:30 - 10:00 RV - Confrontation of G - New technologies in COS - Nanotechnology in PO - Conjunctival tumors EUPO 1 LC - Ocular damage from ACB - Stem cells and MBGE - Grand rounds in OCT-angiography and glaucoma surgery ophthalmology Neuro-ophthalmology
    [Show full text]
  • Treatment Potential for LCA5-Associated Leber Congenital Amaurosis
    Retina Treatment Potential for LCA5-Associated Leber Congenital Amaurosis Katherine E. Uyhazi,1,2 Puya Aravand,1 Brent A. Bell,1 Zhangyong Wei,1 Lanfranco Leo,1 Leona W. Serrano,2 Denise J. Pearson,1,2 Ivan Shpylchak,1 Jennifer Pham,1 Vidyullatha Vasireddy,1 Jean Bennett,1 and Tomas S. Aleman1,2 1Center for Advanced Retinal and Ocular Therapeutics (CAROT) and F.M. Kirby Center for Molecular Ophthalmology, University of Pennsylvania, Philadelphia, PA, USA 2Scheie Eye Institute at The Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA, USA Correspondence: Tomas S. Aleman, PURPOSE. To determine the therapeutic window for gene augmentation for Leber congen- Perelman Center for Advanced ital amaurosis (LCA) associated with mutations in LCA5. Medicine, University of Pennsylvania, 3400 Civic Center METHODS. Five patients (ages 6–31) with LCA and biallelic LCA5 mutations underwent Blvd, Philadelphia, PA 19104, USA; an ophthalmic examination including optical coherence tomography (SD-OCT), full-field [email protected]. stimulus testing (FST), and pupillometry. The time course of photoreceptor degeneration in the Lca5gt/gt mouse model and the efficacy of subretinal gene augmentation therapy Received: November 19, 2019 with AAV8-hLCA5 delivered at postnatal day 5 (P5) (early, n = 11 eyes), P15 (mid, n = 14), Accepted: March 16, 2020 = Published: May 19, 2020 and P30 (late, n 13) were assessed using SD-OCT, histologic study, electroretinography (ERG), and pupillometry. Comparisons were made with the human disease. Citation: Uyhazi KE, Aravand P, Bell BA, et al. Treatment potential for RESULTS. Patients with LCA5-LCA showed a maculopathy with detectable outer nuclear LCA5-associated Leber congenital layer (ONL) in the pericentral retina and at least 4 log units of dark-adapted sensitivity amaurosis.
    [Show full text]
  • Retinal Gene Therapy
    Robert MacLaren – [email protected] 26 Update RETINA contact ChoroideraemiaRETINAL trial shows GENE promise and THERAPY challenges of viral gene replacement approach by Howard Larkin in Milan clinical trial of gene therapy for choroideraemia While choroideraemia is relatively rare, afflicting about one now under way in the UK provides an opportunity in 50,000 in northern Europe with the highest incidence in for ophthalmologists to contribute to what Finland, it is a promising disease entity for gene therapy for could be a revolution in treating genetic retinal several reasons, Prof MacLaren noted. conditions,A Robert E MacLaren, DPhil, FRCS, FRCOphth, of For one, the choroideraemia phenotype is specific and Oxford University, Oxford Eye Hospital and Moorfields Eye instantly recognisable, whereas the appearance of the retina Hospital, London, UK, told the 12th EURETINA Congress. in other types of retinitis pigmentosis is similar regardless of Viral-vector gene therapy holds the promise of curing the gene involved. This makes possible early identification of life-long genetic retinal disorders with a single injection choroideraemia patients. Also, the gene involved, CHM, is 1.9 of replacement genetic material, Prof MacLaren said. The kilobases long, making it an ideal size for delivery by adeno- treatment he developed with Prof Miguel Seabra, Imperial associated viral vectors, which have been shown safe and Courtesy of Robert E MacLaren, DPhil, FRCS, FRCOphth College, London, is the first for choroideraemia, an x effective for retinal applications, Prof MacLaren said. Figure 1: European collaboration. Prof Robert MacLaren (UK) performs the first chromosome-linked degenerative retinal disease leading to In addition, the condition typically progresses slowly, from choroideraemia gene therapy surgery in Oxford with Dr Martin Zinkernagel (Switzerland).
    [Show full text]
  • Notch-Signaling in Retinal Regeneration and Müller Glial Plasticity
    Notch-Signaling in Retinal Regeneration and Müller glial Plasticity DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Kanika Ghai, MS Neuroscience Graduate Studies Program The Ohio State University 2009 Dissertation Committee: Dr. Andy J Fischer, Advisor Dr. Heithem El-Hodiri Dr. Susan Cole Dr. Paul Henion Copyright by Kanika Ghai 2009 ABSTRACT Eye diseases such as blindness, age-related macular degeneration (AMD), diabetic retinopathy and glaucoma are highly prevalent in the developed world, especially in a rapidly aging population. These sight-threatening diseases all involve the progressive loss of cells from the retina, the light-sensing neural tissue that lines the back of the eye. Thus, developing strategies to replace dying retinal cells or prolonging neuronal survival is essential to preserving sight. In this regard, cell-based therapies hold great potential as a treatment for retinal diseases. One strategy is to stimulate cells within the retina to produce new neurons. This dissertation elucidates the properties of the primary support cell in the chicken retina, known as the Müller glia, which have recently been shown to possess stem-cell like properties, with the potential to form new neurons in damaged retinas. However, the mechanisms that govern this stem-cell like ability are less well understood. In order to better understand these properties, we analyze the role of one of the key developmental processes, i.e., the Notch-Signaling Pathway in regulating proliferative, neuroprotective and regenerative properties of Müller glia and bestow them with this plasticity.
    [Show full text]
  • Gene Therapy for Inherited Retinal Diseases
    1278 Review Article on Novel Tools and Therapies for Ocular Regeneration Page 1 of 13 Gene therapy for inherited retinal diseases Yan Nuzbrokh1,2,3, Sara D. Ragi1,2, Stephen H. Tsang1,2,4 1Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York, NY, USA; 2Jonas Children’s Vision Care, New York, NY, USA; 3Renaissance School of Medicine at Stony Brook University, Stony Brook, New York, NY, USA; 4Department of Pathology & Cell Biology, Columbia University Irving Medical Center, New York, NY, USA Contributions: (I) Conception and design: All authors; (II) Administrative support: SH Tsang; (III) Provision of study materials or patients: SH Tsang; (IV) Collection and assembly of data: All authors; (V) Manuscript writing: All authors; (VI) Final approval of manuscript: All authors. Correspondence to: Stephen H. Tsang, MD, PhD. Harkness Eye Institute, Columbia University Medical Center, 635 West 165th Street, Box 212, New York, NY 10032, USA. Email: [email protected]. Abstract: Inherited retinal diseases (IRDs) are a genetically variable collection of devastating disorders that lead to significant visual impairment. Advances in genetic characterization over the past two decades have allowed identification of over 260 causative mutations associated with inherited retinal disorders. Thought to be incurable, gene supplementation therapy offers great promise in treating various forms of these blinding conditions. In gene replacement therapy, a disease-causing gene is replaced with a functional copy of the gene. These therapies are designed to slow disease progression and hopefully restore visual function. Gene therapies are typically delivered to target retinal cells by subretinal (SR) or intravitreal (IVT) injection.
    [Show full text]
  • Congress 2015 Final Programme
    The Royal College of Ophthalmologists Annual Congress of Ophthalmologists College The Royal Innovation Annual Congress 2015 19 - 21 May 2015 19 - 21 May Ophthalmology is changing. We believe the future of ophthalmology is single-use. Advances in understanding. That’s the reason we Final Programme Innovations in patient safety, develop over one hundred technology and technique. single-use products each year and Abstracts Malosa work alongside for pioneering procedures surgeons from throughout the such as ReLEx, DSAEK & ophthalmic profession. Femto-Phaco. 19-21 May 2015 - The ACC Liverpool Developing instruments to So, whatever advances lie ahead, we remain at the enable the procedures of the and Abstracts Final Programme future. cutting edge. +44 (0) 870 3000 555 www.malosa.com RCO Advert 2015.indd 1 19/03/2015 12:39 New AlaHeavy new possibilities see us at Stand J New AlaHeavy, from Alamedics Germany is a new ‘heavy oil’ which addresses some of the shortcomings of similar products that have been available in the past. AlaHeavy is a silicone oil which has been manufactured to be of a higher density than water. AlaHeavy is not a mixture. AlaHeavy is not oil with added density-enhancing surfactants, such as alkanes or alkenes. That means no separation during storage, or in the eye, as well as less chance of an inflammatory reaction within the eye. AlaHeavy also gives you 2 further ‘bonus’ advantages. It exhibits a higher density but lower viscosity than similar products currently on the market. Therefore, not only is it more effective as a heavy tamponade, but it is also easier to handle.
    [Show full text]
  • Pathophysiology and Gene Therapy of the Optic Neuropathy in Wolfram Syndrome Jolanta Jagodzinska
    Pathophysiology and gene therapy of the optic neuropathy in Wolfram Syndrome Jolanta Jagodzinska To cite this version: Jolanta Jagodzinska. Pathophysiology and gene therapy of the optic neuropathy in Wolfram Syndrome. Human health and pathology. Université Montpellier, 2016. English. NNT : 2016MONTT057. tel-02000983 HAL Id: tel-02000983 https://tel.archives-ouvertes.fr/tel-02000983 Submitted on 1 Feb 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. ! Délivré par l’Université de Montpellier Préparée au sein de l’école doctorale Sciences Chimiques et Biologiques pour la Santé et de l’unité de recherche INSERM U1051 Institut des Neurosciences de Montpellier Spécialité : Neurosciences Présentée par Jolanta JAGODZINSKA Pathophysiology and gene therapy of the optic neuropathy in Wolfram Syndrome Soutenue le 22/12/2016 devant le jury composé de Timothy BARRETT, Pr, University of Birmingham Président Sulev KOKS, Pr, University of Tartu Rapporteur Marisol CORRAL-DEBRINSKI, DR2 CNRS, UPMC Paris 06 Examinateur Benjamin DELPRAT, CR1 INSERM, INM, Montpellier Examinateur Agathe ROUBERTIE, PH, CHRU Montpellier Examinateur Cécile DELETTRE-CRIBAILLET, CR1 INSERM, INM, Montpellier Directeur de thèse Christian HAMEL, Pr, PU-PH, CHRU Montpellier Co-directeur de thèse ACKNOWLEDGEMENTS I would like to express deep gratitude to my research supervisor, Dr Cécile Delettre-Cribaillet for her constant advice, trust, motivation, kindness and patience.
    [Show full text]
  • Characterizing the Natural History of Visual Function in Choroideremia Using Microperimetry and Multimodal Retinal Imaging
    Europe PMC Funders Group Author Manuscript Invest Ophthalmol Vis Sci. Author manuscript; available in PMC 2018 March 14. Published in final edited form as: Invest Ophthalmol Vis Sci. 2017 October 01; 58(12): 5575–5583. doi:10.1167/iovs.17-22486. Europe PMC Funders Author Manuscripts Characterizing the Natural History of Visual Function in Choroideremia Using Microperimetry and Multimodal Retinal Imaging Jasleen K. Jolly1,2, Kanmin Xue1,2, Thomas L. Edwards1,2, Markus Groppe1, and Robert E. MacLaren1,2 1Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom; Oxford Biomedical Research Centre 2Oxford Eye Hospital, John Radcliffe Hospital, Oxford, United Kingdom Abstract Purpose—Centripetal retinal degeneration in choroideremia (CHM) leads to early visual field restriction and late central vision loss. The latter marks an acute decline in quality of life but visual prognostication remains challenging. We investigated visual function in CHM by correlating best- corrected visual acuity (BCVA), microperimetry and multimodal imaging. Methods—Fifty-six consecutive CHM patients attending Oxford Eye Hospital were examined with BCVA, 10–2 microperimetry, optical coherence tomography, and fundus autofluorescence (AF). Microperimetry was repeated in 21 eyes and analyzed with Bland-Altman. Kaplan-Meier Europe PMC Funders Author Manuscripts survival plots of eyes retaining 20/20 BCVA were created. Intereye symmetry was assessed. Results—Microperimetry coefficient of repeatability was 1.45 dB. Survival analysis showed an indistinguishable pattern between eyes (median survival 39 years). Macular sensitivity showed a similar decline in right and left eyes, with half-lives of 13.6 years. Zonal analysis showed faster decline nasal to the fovea.
    [Show full text]
  • Visionamerica of Birmingham
    VisionAmerica of Birmingham EYE HEALTH PARTNERS OF ALABAMA AND TENNESSEE TRENTON CLEGHERN, OD, FAAO Our Mission Provide the highest quality of medical and surgical eye care available while advocating the cooperative efforts of optometry and ophthalmology through clinical care, education and research. Multi-specialty medical and surgical eye Care No Primary Care Services Medical eye care Cataract and refractive surgery Cornea surgery Retina Oculoplastics Medical and surgical management of glaucoma Neuro-ophthalmology Pediatrics and strabismus Genetic eye disease and electrophysiological testing VisionAmerica of Birmingham Paul Batson, OD Regional Executive Director Jill Helton, OD Assistant Center Director Trenton Cleghern, OD Consultative Optometrist Rod Nowakowski, OD, PhD Genetic Eye Disease and Electrodiagnostics Donald McCurdy, MD Cataract Surgeon Jeff Fuller, MD Retinal Specialist Irene Ludwig, MD Pediatric and Strabismus Surgeon Matthew Albright, MD Cataract and Cornea Surgeon Dale Brown, MD Retina Specialist Kristin Madonia, MD Neuro-ophthalmologist and Oculoplastics Michael Eddins, MD Cataract Surgeon Anterior Segment/General Medical Eye Care Topical/Clear Cornea Cataract Surgery Same Day Cataract Surgery Toric and Presbyopic IOL’s YAG Capsulotomy Laser Trabeculoplasty Laser Peripheral Iridotomy Pterygium Surgery Uveitis Glaucoma Management Cornea Corneal Ulcers Superficial Keratectomy Intacs for Keratoconus Corneal Transplants Descemet Stripping Endothelial Keratoplasty (DSAEK) Oculoplastics Blepharoplasty Ptosis repair Forehead
    [Show full text]
  • New Trial for Blindness Rewrites the Genetic Code 20 March 2017
    New trial for blindness rewrites the genetic code 20 March 2017 However, a research team led by Professor Robert MacLaren from the University of Oxford has reprogrammed the genetic code of RPGR to make it more stable, but in a way that does not affect its function. This has allowed the gene to be delivered reliably by a viral vector into retinal cells. The current trial is the first in the world to test a treatment for retinitis pigmentosa caused by RPGR. Robert MacLaren, Professor of Ophthalmology at the University of Oxford, who is leading the trial New trial for blindness rewrites the genetic code. Credit: said: "The effect of RPGR-related disease on Shutterstock families with retinitis pigmentosa is devastating and we have spent many years working out how to develop this gene therapy. Changing the genetic code is always undertaken with great caution, but Researchers have started a new gene therapy the new sequence we are using has proven to be clinical trial to treat X-linked retinitis pigmentosa highly effective in our laboratory studies. (XLRP), the most common cause of blindness in young people. "The genetic code for all life on Earth is made up of four letters – G, T, A and C. In RPGR, however, Retinitis pigmentosa is currently untreatable and half of the gene comprises only two letters – A and leads to a slow and irreversible loss of vision. G. This makes the gene very unstable and prone to mutations, making it a lead cause of blindness in The trial is being run by Nightstarx Ltd (Nightstar), patients with retinitis pigmentosa.
    [Show full text]